Passage Bio, Inc.

PASG

US7027122099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 07:00:00 11/03/26 am AEDT			5-day change	1st Jan Change
8.510 ^USD	-3.19%		+6.38%	-27.88%

04/03	Passage Bio FY Income from Operations USD -49.296 Million	RE
03/03	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Passage Bio FY Income from Operations USD -49.296 Million

Published on 03/04/2026 at 12:22 am AEDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Passage Bio, Inc.

04/03	Passage Bio FY Income from Operations USD -49.296 Million	RE
03/03	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/11	Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating	MT
12/11	Wedbush Adjusts Passage Bio Price Target to $32 From $40, Maintains Outperform Rating	MT
11/11	Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11/11	Passage Bio Q3 net loss narrows to $7.7 mln	RE
19/09/25	Passage Bio, Inc. Announces Board Changes	CI
13/08/25	Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	Passage Bio, Inc. Provides Recent Business Highlights	CI
10/07/25	Passage Bio announces 1-for-20 reverse stock split	RE
23/06/25	Passage Bio, Inc. Reports Updated Interim Data from upliFT-D Study and Provides Program Update	CI
14/05/25	Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating	MT
13/05/25	Passage Bio Q1 Income From Operations USD -16.459 Million	RE
13/05/25	Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
13/05/25	Passage Bio, Inc. Announces Treated First FTD-GRN Patient with Dose 2 PBFT02 and Enrolled Second Patient	CI

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâ€™s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Employees

Sector

Biotechnology & Medical Research

More about the company